PMID- 25518349
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20141218
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 72
IP  - 12
DP  - 2014 Dec
TI  - [Peptide vaccination for castration-resistant prostate cancer].
PG  - 2147-51
AB  - Since both tumor cells and host immune cell repertoires are diverse and 
      heterogeneous, immune responses against tumor associated antigens shall be 
      substantially different among individual patients with prostate cancer. 
      Subsequently, selection of suitable peptide vaccines for individual patients 
      based on the pre-existing host immunity before vaccination could induce potent 
      anti-tumor responses capable of providing clinical benefit for prostate cancer 
      patients. We have developed a novel immunotherapeutic approach of personalized 
      peptide vaccination (PPV) in which a maximum of four human leukocyte antigen 
      (HLA)-class IA-matched peptides were selected for vaccination among pooled 
      peptides based on both HLA-class IA type and the pre-existing host immunity 
      before vaccination. We discuss our recent results of clinical studies of peptide 
      vaccination for castration-resistant prostate cancer and the future direction of 
      therapeutic cancer vaccines.
FAU - Koga, Noriko
AU  - Koga N
FAU - Noguchi, Masanori
AU  - Noguchi M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Dendritic Cells/immunology
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms, Castration-Resistant/immunology/*therapy
MH  - *Vaccination
MH  - Vaccines, Subunit/therapeutic use
EDAT- 2014/12/19 06:00
MHDA- 2014/12/31 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2014 Dec;72(12):2147-51.